Barbara Harrison
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Barbara Harrison.
The New England Journal of Medicine | 2013
Rena R. Wing; Paula Bolin; Frederick L. Brancati; George A. Bray; Jeanne M. Clark; Mace Coday; Richard S. Crow; Jeffrey M. Curtis; Caitlin Egan; Mark A. Espeland; Mary Evans; John P. Foreyt; Siran Ghazarian; Edward W. Gregg; Barbara Harrison; Helen P. Hazuda; James O. Hill; Edward S. Horton; S. Van Hubbard; John M. Jakicic; Robert W. Jeffery; Karen C. Johnson; Steven E. Kahn; Abbas E. Kitabchi; William C. Knowler; Cora E. Lewis; Barbara J. Maschak-Carey; Maria G. Montez; Anne Murillo; David M. Nathan
BACKGROUND Weight loss is recommended for overweight or obese patients with type 2 diabetes on the basis of short-term studies, but long-term effects on cardiovascular disease remain unknown. We examined whether an intensive lifestyle intervention for weight loss would decrease cardiovascular morbidity and mortality among such patients. METHODS In 16 study centers in the United States, we randomly assigned 5145 overweight or obese patients with type 2 diabetes to participate in an intensive lifestyle intervention that promoted weight loss through decreased caloric intake and increased physical activity (intervention group) or to receive diabetes support and education (control group). The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for angina during a maximum follow-up of 13.5 years. RESULTS The trial was stopped early on the basis of a futility analysis when the median follow-up was 9.6 years. Weight loss was greater in the intervention group than in the control group throughout the study (8.6% vs. 0.7% at 1 year; 6.0% vs. 3.5% at study end). The intensive lifestyle intervention also produced greater reductions in glycated hemoglobin and greater initial improvements in fitness and all cardiovascular risk factors, except for low-density-lipoprotein cholesterol levels. The primary outcome occurred in 403 patients in the intervention group and in 418 in the control group (1.83 and 1.92 events per 100 person-years, respectively; hazard ratio in the intervention group, 0.95; 95% confidence interval, 0.83 to 1.09; P=0.51). CONCLUSIONS An intensive lifestyle intervention focusing on weight loss did not reduce the rate of cardiovascular events in overweight or obese adults with type 2 diabetes. (Funded by the National Institutes of Health and others; Look AHEAD ClinicalTrials.gov number, NCT00017953.).
Diabetes Care | 2007
Mark A. Espeland; Xavier Pi-Sunyer; George L. Blackburn; Frederick L. Brancati; George A. Bray; Renee Bright; Jeanne M. Clark; Jeffrey M. Curtis; John P. Foreyt; Kathryn Graves; Steven M. Haffner; Barbara Harrison; James O. Hill; Edward S. Horton; John M. Jakicic; Robert W. Jeffery; Karen C. Johnson; Steven E. Kahn; David E. Kelley; Abbas E. Kitabchi; William C. Knowler; Cora E. Lewis; Barbara J. Maschak-Carey; Brenda Montgomery; David M. Nathan; Jennifer Patricio; Anne L. Peters; J. Bruce Redmon; Rebecca S. Reeves; Donna H. Ryan
OBJECTIVE—The effectiveness of intentional weight loss in reducing cardiovascular disease (CVD) events in type 2 diabetes is unknown. This report describes 1-year changes in CVD risk factors in a trial designed to examine the long-term effects of an intensive lifestyle intervention on the incidence of major CVD events. RESEARCH DESIGN AND METHODS—This study consisted of a multicentered, randomized, controlled trial of 5,145 individuals with type 2 diabetes, aged 45–74 years, with BMI >25 kg/m2 (>27 kg/m2 if taking insulin). An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. RESULTS—Participants assigned to ILI lost an average 8.6% of their initial weight vs. 0.7% in DSE group (P < 0.001). Mean fitness increased in ILI by 20.9 vs. 5.8% in DSE (P < 0.001). A greater proportion of ILI participants had reductions in diabetes, hypertension, and lipid-lowering medicines. Mean A1C dropped from 7.3 to 6.6% in ILI (P < 0.001) vs. from 7.3 to 7.2% in DSE. Systolic and diastolic pressure, triglycerides, HDL cholesterol, and urine albumin-to-creatinine ratio improved significantly more in ILI than DSE participants (all P < 0.01). CONCLUSIONS—At 1 year, ILI resulted in clinically significant weight loss in people with type 2 diabetes. This was associated with improved diabetes control and CVD risk factors and reduced medicine use in ILI versus DSE. Continued intervention and follow-up will determine whether these changes are maintained and will reduce CVD risk.
JAMA Internal Medicine | 2000
Charles J. Billington; Leonard H. Epstein; Norma J. Goodwin; James O. Hill; F. X. Pi-Sunyer; Barbara J. Rolls; Judith S. Stern; Thomas A. Wadden; Roland L. Weinsier; G. T. Wilson; Rena R. Wing; Susan Z. Yanovski; Van S. Hubbard; Jay H. Hoofnagle; James E. Everhart; Barbara Harrison
JAMA Internal Medicine | 2000
Susan Z. Yanovski; Charles J. Billington; Leonard H. Epstein; Norma J. Goodwin; James O. Hill; F. Xavier Pi-Sunyer; Barbara J. Rolls; Judith S. Stern; Thomas A. Wadden; Roland L. Weinsier; G. Terence Wilson; Rena R. Wing; S. Van Hubbard; Jay H. Hoofnagle; James E. Everhart; Barbara Harrison
Analytical Biochemistry | 1986
Barbara Harrison; Steven B. Zimmerman
Obesity Research | 1994
Barbara Harrison; Van S. Hubbard